Pair Name	Periplocin, Gemcitabine
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	BIRC5	hsa332
	Up-regulation	Cleavage	CASP8	hsa841
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CDK2	hsa1017
	Down-regulation	Expression	CDK4	hsa1019
	Down-regulation	Expression	CDK6	hsa1021
	Down-regulation	Expression	FOS	hsa2353
	Down-regulation	Expression	HMOX1	hsa3162
	Up-regulation	Expression	KEAP1	hsa9817
	Down-regulation	Expression	NFE2L2	hsa4780
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	PRDX1	hsa5052
	Down-regulation	Phosphorylation	RELA	hsa5970
In Vitro Model	PANC-1	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0480
	HEK293	Healthy	Homo sapiens (Human)	CVCL_0045
In Vivo Model	PANC-1 and PANC-GR cell suspension (4×10⁶ cells per mouse mix with Matrigel 1:1) was subcutaneously injected into the right flank of mice and tumors were maintained until tumor volume reached 80 mm3.
Result	Periplocin exerts antitumor activity by regulating Nrf2-mediated signaling pathway in gemcitabine-resistant pancreatic cancer cells